Takeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional FoodBusiness Wire • 04/08/24
Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAEPRNewsWire • 03/27/24
Takeda Announces Candidates for Board of Directors at Upcoming Shareholders MeetingBusiness Wire • 03/26/24
Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)Business Wire • 03/26/24
Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALLBusiness Wire • 03/19/24
Advanced Infusion Care (AIC) Now Offers Takeda's GLASSIA® [Alpha1-Proteinase Inhibitor (Human)] and ARALAST® NP [Alpha1-Proteinase Inhibitor (Human)]Business Wire • 03/18/24
Newer Treatments In Alpha-1 Antitrypsin Deficiency: $2.5 Billion/Year Market Size By 2032Seeking Alpha • 03/14/24
Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune ThrombocytopeniaBusiness Wire • 03/13/24
Takeda Pharmaceutical Co. (TAK) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 03/11/24
Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?Zacks Investment Research • 03/11/24
Japan's Takeda partners with India's Biological E. to boost dengue vaccine productionReuters • 02/27/24
Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic AreasBusiness Wire • 02/27/24
FDA Approves Takeda's EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE)Business Wire • 02/12/24
Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024Business Wire • 02/08/24
Takeda Announces Third-Quarter FY2023 Results; On-Track Towards Full-Year Management Guidance With Strong Momentum in Growth & Launch ProductsBusiness Wire • 02/01/24
Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology AssetAccesswire • 01/31/24
Takeda's GAMMAGARD LIQUID® Approved by U.S. FDA for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Business Wire • 01/29/24
Takeda's HYQVIA® Approved by European Commission as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Business Wire • 01/29/24
Cognizant Helping to Modernize Infrastructure and Application Management as Part of Takeda's Digital TransformationPRNewsWire • 01/25/24